Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An iron regulatory gene signature predicts outcome in breast cancer.
Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R Jr, Torti SV, Torti FM. Miller LD, et al. Among authors: black ma. Cancer Res. 2011 Nov 1;71(21):6728-37. doi: 10.1158/0008-5472.CAN-11-1870. Epub 2011 Aug 29. Cancer Res. 2011. PMID: 21875943 Free PMC article.
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness.
Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM. Miller LD, et al. Among authors: black ma. Cancer Immunol Res. 2016 Jul;4(7):600-10. doi: 10.1158/2326-6066.CIR-15-0149. Epub 2016 Apr 28. Cancer Immunol Res. 2016. PMID: 27197066 Free PMC article.
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA. Caldon CE, et al. Among authors: black ma. Mol Cancer Ther. 2012 Jul;11(7):1488-99. doi: 10.1158/1535-7163.MCT-11-0963. Epub 2012 May 7. Mol Cancer Ther. 2012. PMID: 22564725
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer.
Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, Gatza ML, Perou CM, Page DB, Triozzi P, Miller LD. Thomas A, et al. Among authors: black ma. Oncoimmunology. 2018 Jul 30;7(10):e1490854. doi: 10.1080/2162402X.2018.1490854. eCollection 2018. Oncoimmunology. 2018. PMID: 30386679 Free PMC article.
YB-1, the E2F pathway, and regulation of tumor cell growth.
Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW. Lasham A, et al. Among authors: black ma. J Natl Cancer Inst. 2012 Jan 18;104(2):133-46. doi: 10.1093/jnci/djr512. Epub 2011 Dec 28. J Natl Cancer Inst. 2012. PMID: 22205655 Free PMC article.
Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes.
Pullikuth AK, Routh ED, Zimmerman KD, Chifman J, Chou JW, Soike MH, Jin G, Su J, Song Q, Black MA, Print C, Bedognetti D, Howard-McNatt M, O'Neill SS, Thomas A, Langefeld CD, Sigalov AB, Lu Y, Miller LD. Pullikuth AK, et al. Among authors: black ma. Front Oncol. 2021 Dec 8;11:734959. doi: 10.3389/fonc.2021.734959. eCollection 2021. Front Oncol. 2021. PMID: 34956864 Free PMC article.
183 results